TY - CHAP
T1 - Therapeutic Use of Estrogen Receptor β Agonists in Prevention and Treatment of Endocrine Therapy Resistant Breast Cancers
T2 - Observations From Preclinical Models
AU - Ramasamy, Kumaraguruparan
AU - Samayoa, Cathy
AU - Krishnegowda, Naveen
AU - Tekmal, Rajeshwar R.
N1 - Publisher Copyright:
© 2017
PY - 2017
Y1 - 2017
N2 - Breast cancer is one of the most common cancers in the world. The majority of breast cancers express estrogen receptor (ER)α and endocrine therapy is the primary therapeutic approach to treat ER positive breast cancers. However, developing resistance and side effects are common events of these therapeutic strategies. Recent studies have evaluated the role of ERs sub types and demonstrated that ERα is a tumorigenic and ERβ functions as a tumor suppressor. In recent years, preclinical studies focused on the use of natural and synthetic ERβ agonists to treat wide varieties of cancers, including breast cancer. Successful studies conducted so far, have established that ERβ agonists are effective both alone and in combination with chemotherapeutic agents. These data have suggested that use of ERβ agonists in combination with endocrine therapy may be an effective treatment strategy in hormone receptor positive breast cancers. The present review focuses on the tumor suppressive role of ERβ and the efficacy and mechanisms of several natural and synthetic ERβ agonists against breast cancer.
AB - Breast cancer is one of the most common cancers in the world. The majority of breast cancers express estrogen receptor (ER)α and endocrine therapy is the primary therapeutic approach to treat ER positive breast cancers. However, developing resistance and side effects are common events of these therapeutic strategies. Recent studies have evaluated the role of ERs sub types and demonstrated that ERα is a tumorigenic and ERβ functions as a tumor suppressor. In recent years, preclinical studies focused on the use of natural and synthetic ERβ agonists to treat wide varieties of cancers, including breast cancer. Successful studies conducted so far, have established that ERβ agonists are effective both alone and in combination with chemotherapeutic agents. These data have suggested that use of ERβ agonists in combination with endocrine therapy may be an effective treatment strategy in hormone receptor positive breast cancers. The present review focuses on the tumor suppressive role of ERβ and the efficacy and mechanisms of several natural and synthetic ERβ agonists against breast cancer.
KW - ER
KW - ERβ agonists
KW - estrogen receptors
KW - prevention of mammary cancer
KW - restoring sensitivity to endocrine therapy breast tumors
KW - tumor suppressor
UR - http://www.scopus.com/inward/record.url?scp=85030764851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030764851&partnerID=8YFLogxK
U2 - 10.1016/bs.pmbts.2017.08.002
DO - 10.1016/bs.pmbts.2017.08.002
M3 - Chapter
C2 - 29096893
AN - SCOPUS:85030764851
T3 - Progress in Molecular Biology and Translational Science
SP - 177
EP - 194
BT - Progress in Molecular Biology and Translational Science
PB - Elsevier B.V.
ER -